



Solv^{4U}


Technology Partnerships

From suspension to solution

Solv^{4U} is a **new technology partnership offering** by Marinomed Biotech AG.

Solv^{4U} supports formulation development of hydrophobic **Active Pharmaceutical Ingredients (APIs)**.

Solv^{4U} is based on the proprietary **innovative Marinosolv[®] solubilisation technology** platform.



Marinosolv[®] formulation technology

About Marinosolv[®]

- o **Patent protected** drug delivery platform
- o **Clinically validated**
- o Based on **micelles composed of excipients** from natural sources proven to be clinically safe
- o For **small molecules and peptides** at all stages of NCE/API development

Suitable for

- o Re-formulation and repurposing of established APIs enabling **patent life cycle extension** for established compounds
- o **Locally applied, locally acting** drugs for sensitive tissues
- o **Systemic administration routes**



Solve the un(dis)solvable
www.solv4u.com



Benefits

- **Increased solubility** directly correlates with **increased bioavailability** of API.
- Results in a **faster onset of action**.
- **Reduction of the administered dose**
- **Well tolerated**, for local and **systemic** administration routes

FASTER
ONSET
OF ACTION

REDUCED
DOSE


EASY
SCALABLE

SUSTAIN-
ABLE


Mode of action

The Marinosolv® matrix is individually composed for an optimized formulation for each drug substance.

Marinosolv® formulation:



Solubilization of API:





Solubility enhancement

Marinosolv® works with hardly water-soluble APIs from **different substance classes**. Marinomed has validated the technology through its **own product development** projects improving established APIs. In addition, numerous compounds have been solubilised successfully in **client projects**.

Corticosteroids

Budesonide > 10-fold
Fluticasone > 50-fold
Mometasone 100-fold

Macrolide immunosuppressants

Cyclosporin A 30-fold
Pimecrolimus 80-fold
Tacrolimus 200-fold

Cancer therapeutics

Pazopanib 40000-fold
Paclitaxel > 10-fold

Work in progress

Macrolide antibiotics
Small peptides

Phyto-pharmaceuticals

Cannabidiol > 300-fold
Curcumin > 1000-fold
Digitoxin > 110-fold
Rutin > 180-fold


Marinosolv® solubility enhancement in comparison to solubility in water

Application routes



Local

(e.g. intranasal/ocular)



Systemic

(e.g. oral/intravenous)


Dosage forms



Solid



Liquid solution Semi-solid



is available for development partnerships

Solv^{4U} technology partnerships are the right choice **if you aim**

- o to **re-formulate or repurpose** established off-patent APIs or
- o to enhance the bioavailability of **New Chemical Entities** (NCEs) for exploratory preclinical studies.

We focus on **your individual needs** and consider your requirements for subsequent development stages, such as process **up-scaling**, intended **administration routes** and **manufacturing**.

Formulation services at Marinomed start with a **feasibility study** at reasonable costs and with defined timelines.

For more information please contact:

Marinomed Biotech AG
Susanne Bach, PhD
Business Development

Hovengasse 25, 2100 Korneuburg, Austria
E-Mail: bd@marinomed.com
Tel: +43 2262 90300

About Marinomed Biotech AG

Marinomed Biotech AG (Korneuburg) is an Austrian science-based biotech company with globally marketed therapeutics and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). The company focuses on the development of innovative products based on two patent-protected technology platforms, Marinosolv® and Carragelose®. www.marinomed.com



Solve the un(dis)solvable
www.solv4u.com

